Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
Psychedelic profiles: ibogaine; Eleusis goes public via merger, creating a US$450 million company; The future of psychedelic medicine will be drugs you’ve never heard of.
Psychedelic profiles: ketamine; Italian officials certify signatures for psilocybin referendum; Sixty-five per cent of Americans with mental health conditions want access to psychedelics.
Psychedelic profiles: psilocybin; Awakn releases data from Phase II study for alcohol use disorder; Canada amends Special Access Program for psychedelic medicines.
Gwella on making microdosing mainstream; The MHRA releases new guidance on using data in clinical trials; Psychedelics: the newest tool in nuclear negotiations?
Healthcare professionals’ perception of psychedelic medicines; Australian regulator refuses to reclassify psychedelic compounds; COMPASS shares further data from COMP360 Phase IIb trial
Is the NHS ready to embrace psychedelics as medicine?; DEA again boosts 2022 production goals for psychedelic medicines; MAPS and Vine Ventures raise US$70m through revenue sharing model
Has psychedelic research reached a tipping point?; Psychedelics can change humanity for the better; Seelos Therapeutics raises US$20m in private placement
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
Subscribe to the Psychedelics Newsletter
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.